CoChat
Sign Up
Cited by 76Blood properties and coagulationBlood Coagulation and Thrombosis MechanismsBarrier Structure and Function Studies

Breaking boundaries—coagulation and fibrinolysis at the neurovascular interface

Open access
Bardehle, Sophia, Rafalski, Victoria A., Akassoglou, Katerina·2015·Frontiers in Cellular Neuroscience
DOI 10.3389/fncel.2015.00354PMC PMC4584986
Open this paper in CoChat — free accountOpen PDF

Abstract

Blood proteins at the neurovascular unit (NVU) are emerging as important molecular determinants of communication between the brain and the immune system. Over the past two decades, roles for the plasminogen activation (PA)/plasmin system in fibrinolysis have been extended from peripheral dissolution of blood clots to the regulation of central nervous system (CNS) functions in physiology and disease. In this review, we discuss how fibrin and its proteolytic degradation affect neuroinflammatory, degenerative and repair processes. In particular, we focus on novel functions of fibrin-the final product of the coagulation cascade and the main substrate of plasmin-in the activation of immune responses and trafficking of immune cells into the brain. We also comment on the suitability of the coagulation and fibrinolytic systems as potential biomarkers and drug targets in diseases, such as multiple sclerosis (MS), Alzheimer's disease (AD) and stroke. Studying coagulation and fibrinolysis as major molecular pathways that regulate cellular functions at the NVU has the potential to lead to the development of novel strategies for the detection and treatment of neurologic diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fncel.2015.00354

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Fibrinogen and its polymeric form fibrin can activate integrin receptors on glial cells and neurons to inhibit regeneration, or receptors on microglia and bone-derived macrophages to exacerbate neuroinflammation and induce antigen-presenting genes.

    “For example, fibrinogen and its polymeric form fibrin can activate integrin receptors on glial cells and neurons to inhibit regeneration (45, 522), or receptors on microglia and bone-derived macrophages to exacerbate neuroinflammation and induce antigen-presenting genes (45, 132, 510).”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [45]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 105

  1. Abu Fanne R. Nassar T. Yarovoi S. Rayan A. Lamensdorf I. Karakoveski M.. (2010). Blood-brain barrier permeability and tPA-mediated neurotoxicity. Neuropharmacology 58, 972– 980. 10.1016/j.neuropharm.2009.12.017 20060006 PMC4423729 · DOI
  2. Adams R. A. Bauer J. Flick M. J. Sikorski S. L. Nuriel T. Lassmann H.. (2007). The fibrin-derived gamma377–395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J. Exp. Med. 204, 571– 582. 10.1084/jem.20061931 17339406 PMC2137908 · DOI · Paper page
  3. Adams R. A. Passino M. Sachs B. D. Nuriel T. Akassoglou K. (2004). Fibrin mechanisms and functions in nervous system pathology. Mol. Interv. 4, 163– 176. 10.1124/mi.4.3.6 15210870 · DOI
  4. Ahn H. J. Glickman J. F. Poon K. L. Zamolodchikov D. Jno-Charles O. C. Norris E. H.. (2014). A novel Abeta-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer’s disease mice. J. Exp. Med. 211, 1049– 1062. 10.1084/jem.20131751 24821909 PMC4042638 · DOI
  5. Ahn H. J. Zamolodchikov D. Cortes-Canteli M. Norris E. H. Glickman J. F. Strickland S. (2010). Alzheimer’s disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc. Natl. Acad. Sci. U S A 107, 21812– 21817. 10.1073/pnas.1010373107 21098282 PMC3003082 · DOI
  6. Akassoglou K. (2015). Coagulation takes center stage in inflammation. Blood 125, 419– 420. 10.1182/blood-2014-11-609222 25593329 PMC4296004 · DOI
  7. Akassoglou K. Adams R. A. Bauer J. Mercado P. Tseveleki V. Lassmann H.. (2004). Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc. Natl. Acad. Sci. U S A 101, 6698– 6703. 10.1073/pnas.0303859101 15096619 PMC404108 · DOI
  8. Akassoglou K. Akpinar P. Murray S. Strickland S. (2003). Fibrin is a regulator of schwann cell migration after sciatic nerve injury in mice. Neurosci. Lett. 338, 185– 188. 10.1016/s0304-3940(02)01387-3 12581827 · DOI
  9. Akassoglou K. Kombrinck K. W. Degen J. L. Strickland S. (2000). Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury. J. Cell Biol. 149, 1157– 1166. 10.1083/jcb.149.5.1157 10831618 PMC2174825 · DOI
  10. Akassoglou K. Yu W. M. Akpinar P. Strickland S. (2002). Fibrin inhibits peripheral nerve remyelination by regulating schwann cell differentiation. Neuron 33, 861– 875. 10.1016/s0896-6273(02)00617-7 11906694 · DOI
  11. Aksungar F. B. Topkaya A. E. Yildiz Z. Sahin S. Turk U. (2008). Coagulation status and biochemical and inflammatory markers in multiple sclerosis. J. Clin. Neurosci. 15, 393– 397. 10.1016/j.jocn.2007.02.090 18258432 · DOI
  12. Alabanza L. M. Bynoe M. S. (2012). Thrombin induces an inflammatory phenotype in a human brain endothelial cell line. J. Neuroimmunol. 245, 48– 55. 10.1016/j.jneuroim.2012.02.004 22381244 PMC3608467 · DOI
  13. Belayev L. Busto R. Zhao W. Ginsberg M. D. (1996). Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res. 739, 88– 96. 10.1016/s0006-8993(96)00815-3 8955928 · DOI
  14. Bignami A. Cella G. Chi N. H. (1982). Plasminogen activators in rat neural tissues during development and in wallerian degeneration. Acta Neuropathol. 58, 224– 228. 10.1007/bf00690805 6891551 · DOI
  15. Bugge T. H. Flick M. J. Daugherty C. C. Degen J. L. (1995). Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 9, 794– 807. 10.1101/gad.9.7.794 7705657 · DOI
  16. Bugge T. H. Kombrinck K. W. Flick M. J. Daugherty C. C. Danton M. J. Degen J. L. (1996). Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 87, 709– 719. 10.1016/s0092-8674(00)81390-2 8929539 · DOI
  17. Carroll P. M. Tsirka S. E. Richards W. G. Frohman M. A. Strickland S. (1994). The mouse tissue plasminogen activator gene 5’ flanking region directs appropriate expression in development and a seizure-enhanced response in the CNS. Development 120, 3173– 3183. 7720560
  18. Castellino F. J. Ploplis V. A. (2005). Structure and function of the plasminogen/plasmin system. Thromb. Haemost. 93, 647– 654. 10.1160/th04-12-0842 15841308 · DOI
  19. Cesarman-Maus G. Hajjar K. A. (2005). Molecular mechanisms of fibrinolysis. Br. J. Haematol. 129, 307– 321. 10.1111/j.1365-2141.2005.05444.x 15842654 · DOI
  20. Chen B. Friedman B. Whitney M. A. Winkle J. A. Lei I. F. Olson E. S.. (2012). Thrombin activity associated with neuronal damage during acute focal ischemia. J. Neurosci. 32, 7622– 7631. 10.1523/jneurosci.0369-12.2012 22649241 PMC3383068 · DOI
  21. Conti A. Sanchez-Ruiz Y. Bachi A. Beretta L. Grandi E. Beltramo M.. (2004). Proteome study of human cerebrospinal fluid following traumatic brain injury indicates fibrin(ogen) degradation products as trauma-associated markers. J. Neurotrauma 21, 854– 863. 10.1089/0897715041526212 15307898 · DOI
  22. Cortes-Canteli M. Mattei L. Richards A. T. Norris E. H. Strickland S. (2015). Fibrin deposited in the Alzheimer’s disease brain promotes neuronal degeneration. Neurobiol. Aging 36, 608– 617. 10.1016/j.neurobiolaging.2014.10.030 25475538 PMC4315732 · DOI
  23. Cortes-Canteli M. Paul J. Norris E. H. Bronstein R. Ahn H. J. Zamolodchikov D.. (2010). Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer’s disease. Neuron 66, 695– 709. 10.1016/j.neuron.2010.05.014 20547128 PMC2895773 · DOI · Paper page
  24. Craig-Schapiro R. Kuhn M. Xiong C. Pickering E. H. Liu J. Misko T. P.. (2011). Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer’s disease diagnosis and prognosis. PLoS One 6: e18850. 10.1371/journal.pone.0018850 21526197 PMC3079734 · DOI
  25. Cristante E. McArthur S. Mauro C. Maggioli E. Romero I. A. Wylezinska-Arridge M.. (2013). Identification of an essential endogenous regulator of blood-brain barrier integrity and its pathological and therapeutic implications. Proc. Natl. Acad. Sci. U S A 110, 832– 841. 10.1073/pnas.1209362110 23277546 PMC3549094 · DOI
  26. Cullen K. M. Kócsi Z. Stone J. (2006). Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages. Neurobiol. Aging 27, 1786– 1796. 10.1016/j.neurobiolaging.2005.10.016 17063559 · DOI
  27. Cuzner M. L. Opdenakker G. (1999). Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J. Neuroimmunol. 94, 1– 14. 10.1016/s0165-5728(98)00241-0 10376931 · DOI
  28. Dallasta L. M. Pisarov L. A. Esplen J. E. Werley J. V. Moses A. V. Nelson J. A.. (1999). Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am. J. Pathol. 155, 1915– 1927. 10.1016/s0002-9440(10)65511-3 10595922 PMC1866950 · DOI
  29. Daneman R. Prat A. (2015). The blood-brain barrier. Cold Spring Harb. Perspect. Biol. 7: a020412. 10.1101/cshperspect.a020412 25561720 PMC4292164 · DOI · Paper page
  30. Davalos D. Akassoglou K. (2012). Fibrinogen as a key regulator of inflammation in disease. Semin. Immunopathol. 34, 43– 62. 10.1007/s00281-011-0290-8 22037947 · DOI
  31. Davalos D. Baeten K. M. Whitney M. A. Mullins E. S. Friedman B. Olson E. S.. (2014). Early detection of thrombin activity in neuroinflammatory disease. Ann. Neurol. 75, 303– 308. 10.1002/ana.24078 24740641 PMC4049631 · DOI
  32. Davalos D. Ryu J. K. Merlini M. Baeten K. M. Le Moan N. Petersen M. A.. (2012). Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat. Commun. 3: 1227. 10.1038/ncomms2230 23187627 PMC3514498 · DOI · Paper page
  33. Dohgu S. Takata F. Matsumoto J. Oda M. Harada E. Watanabe T.. (2011). Autocrine and paracrine up-regulation of blood-brain barrier function by plasminogen activator inhibitor-1. Microvasc. Res. 81, 103– 107. 10.1016/j.mvr.2010.10.004 21036181 · DOI
  34. East E. Baker D. Pryce G. Lijnen H. R. Cuzner M. L. Gverić D. (2005). A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. Am. J. Pathol. 167, 545– 554. 10.1016/s0002-9440(10)62996-3 16049338 PMC1603566 · DOI
  35. East E. Gverić D. Baker D. Pryce G. Lijnen H. R. Cuzner M. L. (2008). Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation. Neuropathol. Appl. Neurobiol. 34, 216– 230. 10.1111/j.1365-2990.2007.00889.x 17983428 · DOI
  36. Elster A. D. Moody D. M. (1990). Early cerebral infarction: gadopentetate dimeglumine enhancement. Radiology 177, 627– 632. 10.1148/radiology.177.3.2243961 2243961 · DOI
  37. Fugate J. E. Rabinstein A. A. (2014). Update on intravenous recombinant tissue plasminogen activator for acute ischemic stroke. Mayo Clin. Proc. 89, 960– 972. 10.1016/j.mayocp.2014.03.001 24775222 · DOI
  38. Gaitán M. I. Shea C. D. Evangelou I. E. Stone R. D. Fenton K. M. Bielekova B.. (2011). Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. Ann. Neurol. 70, 22– 29. 10.1002/ana.22472 21710622 PMC3143223 · DOI · Paper page
  39. Gay D. Esiri M. (1991). Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain 114, 557– 572. 10.1093/brain/114.1.557 2004256 · DOI
  40. Grossman R. I. Braffman B. H. Brorson J. R. Goldberg H. I. Silberberg D. H. Gonzalez-Scarano F. (1988). Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology 169, 117– 122. 10.1148/radiology.169.1.3420246 3420246 · DOI
  41. Gveric D. Herrera B. Petzold A. Lawrence D. A. Cuzner M. L. (2003). Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain 126, 1590– 1598. 10.1093/brain/awg167 12805124 · DOI
  42. Han M. H. Hwang S. I. Roy D. B. Lundgren D. H. Price J. V. Ousman S. S.. (2008). Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451, 1076– 1081. 10.1038/nature06559 18278032 · DOI
  43. Hultman K. Cortes-Canteli M. Bounoutas A. Richards A. T. Strickland S. Norris E. H. (2014). Plasmin deficiency leads to fibrin accumulation and a compromised inflammatory response in the mouse brain. J. Thromb. Haemost. 12, 701– 712. 10.1111/jth.12553 24612416 PMC4120644 · DOI
  44. Hultman K. Strickland S. Norris E. H. (2013). The APOE varepsilon4/varepsilon4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer’s disease patients. J. Cereb. Blood Flow Metab. 33, 1251– 1258. 10.1038/jcbfm.2013.76 23652625 PMC3734776 · DOI · Paper page
  45. Ill-Raga G. Palomer E. Ramos-Fernández E. Guix F. X. Bosch-Morató M. Guivernau B.. (2015). Fibrinogen nitrotyrosination after ischemic stroke impairs thrombolysis and promotes neuronal death. Biochim. Biophys. Acta 1852, 421– 428. 10.1016/j.bbadis.2014.12.007 25500153 · DOI
  46. Jennewein C. Tran N. Paulus P. Ellinghaus P. Eble J. A. Zacharowski K. (2011). Novel aspects of fibrin(ogen) fragments during inflammation. Mol. Med. 17, 568– 573. 10.2119/molmed.2010.00146 21210072 PMC3105136 · DOI
  47. Kaczmarek E. Lee M. H. McDonagh J. (1993). Initial interaction between fibrin and tissue plasminogen activator (t-PA). The Gly-Pro-Arg-Pro binding site on fibrin(ogen) is important for t-PA activity. J. Biol. Chem. 268, 2474– 2479. 8428923
  48. Kaur J. Tuor U. I. Zhao Z. Barber P. A. (2011). Quantitative MRI reveals the elderly ischemic brain is susceptible to increased early blood-brain barrier permeability following tissue plasminogen activator related to claudin 5 and occludin disassembly. J. Cereb. Blood Flow Metab. 31, 1874– 1885. 10.1038/jcbfm.2011.79 21610723 PMC3185885 · DOI
  49. Kim P. Y. Tieu L. D. Stafford A. R. Fredenburgh J. C. Weitz J. I. (2012). A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator. J. Biol. Chem. 287, 4652– 4661. 10.1074/jbc.m111.317719 22187433 PMC3281636 · DOI
  50. Kirk J. Plumb J. Mirakhur M. McQuaid S. (2003). Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J. Pathol. 201, 319– 327. 10.1002/path.1434 14517850 · DOI · Paper page
  51. Körschenhausen D. A. Hampel H. J. Ackenheil M. Penning R. Muller N. (1996). Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophr. Res. 19, 103– 109. 10.1016/0920-9964(95)00073-9 8789908 · DOI
  52. Kwaan H. C. (2014). From fibrinolysis to the plasminogen-plasmin system and beyond: a remarkable growth of knowledge, with personal observations on the history of fibrinolysis. Semin. Thromb. Hemost. 40, 585– 591. 10.1055/s-0034-1383545 25000957 · DOI
  53. Lakhan S. E. Kirchgessner A. Tepper D. Leonard A. (2013). Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. Front. Neurol. 4: 32. 10.3389/fneur.2013.00032 23565108 PMC3615191 · DOI
  54. Lee K. R. Kawai N. Kim S. Sagher O. Hoff J. T. (1997). Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability and cell survival in a rat model. J. Neurosurg. 86, 272– 278. 10.3171/jns.1997.86.2.0272 9010429 · DOI
  55. Liguori M. Qualtieri A. Tortorella C. Direnzo V. Bagala A. Mastrapasqua M.. (2014). Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration. PLoS One 9: e103984. 10.1371/journal.pone.0103984 25098164 PMC4123901 · DOI
  56. Liu D. Z. Ander B. P. Xu H. Shen Y. Kaur P. Deng W.. (2010). Blood-brain barrier breakdown and repair by Src after thrombin-induced injury. Ann. Neurol. 67, 526– 533. 10.1002/ana.21924 20437588 PMC2919346 · DOI
  57. Liu J. Y. Thom M. Catarino C. B. Martinian L. Figarella-Branger D. Bartolomei F.. (2012). Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain 135, 3115– 3133. 10.1093/brain/aws147 22750659 · DOI
  58. Lu W. Bhasin M. Tsirka S. E. (2002). Involvement of tissue plasminogen activator in onset and effector phases of experimental allergic encephalomyelitis. J. Neurosci. 22, 10781– 10789. 12486171 PMC4002885
  59. Mahley R. W. Huang Y. (2012). Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron 76, 871– 885. 10.1016/j.neuron.2012.11.020 23217737 PMC4891195 · DOI · Paper page
  60. Marik C. Felts P. A. Bauer J. Lassmann H. Smith K. J. (2007). Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 130, 2800– 2815. 10.1093/brain/awm236 17956913 PMC2981817 · DOI · Paper page
  61. Massberg S. Enders G. Matos F. C. Tomic L. I. Leiderer R. Eisenmenger S.. (1999). Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood 94, 3829– 3838. 10572098
  62. Melchor J. P. Pawlak R. Strickland S. (2003). The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J. Neurosci. 23, 8867– 8871. 14523088 PMC6740393
  63. Melchor J. P. Strickland S. (2005). Tissue plasminogen activator in central nervous system physiology and pathology. Thromb. Haemost. 93, 655– 660. 10.1160/th04-12-0838 15841309 PMC1383744 · DOI
  64. Miller D. H. Rudge P. Johnson G. Kendall B. E. Macmanus D. G. Moseley I. F.. (1988). Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 111, 927– 939. 10.1093/brain/111.4.927 3401689 · DOI
  65. Morrow D. A. Braunwald E. Bonaca M. P. Ameriso S. F. Dalby A. J. Fish M. P.. (2012). Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366, 1404– 1413. 10.1056/NEJMoa1200933 22443427 · DOI
  66. Muradashvili N. Tyagi N. Tyagi R. Munjal C. Lominadze D. (2011). Fibrinogen alters mouse brain endothelial cell layer integrity affecting vascular endothelial cadherin. Biochem. Biophys. Res. Commun. 413, 509– 514. 10.1016/j.bbrc.2011.07.133 21920349 PMC3190052 · DOI
  67. Niego B. Freeman R. Puschmann T. B. Turnley A. M. Medcalf R. L. (2012). t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. Blood 119, 4752– 4761. 10.1182/blood-2011-07-369512 22262761 · DOI
  68. Oh S. B. Byun C. J. Yun J. H. Jo D. G. Carmeliet P. Koh J. Y.. (2014a). Tissue plasminogen activator arrests Alzheimer’s disease pathogenesis. Neurobiol. Aging 35, 511– 519. 10.1016/j.neurobiolaging.2013.09.020 24126163 · DOI
  69. Oh J. Lee H. J. Song J. H. Park S. I. Kim H. (2014b). Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer’s disease. Exp. Gerontol. 60, 87– 91. 10.1016/j.exger.2014.10.004 25304332 · DOI
  70. Paterson P. Y. (1976). Experimental allergic encephalomyelitis: role of fibrin deposition in immunopathogenesis of inflammation in rats. Fed. Proc. 35, 2428– 2434. 61895
  71. Paterson P. Y. Koh C. S. Kwaan H. C. (1987). Role of the clotting system in the pathogenesis of neuroimmunologic disease. Fed. Proc. 46, 91– 96. 2433164
  72. Patibandla P. K. Tyagi N. Dean W. L. Tyagi S. C. Roberts A. M. Lominadze D. (2009). Fibrinogen induces alterations of endothelial cell tight junction proteins. J. Cell. Physiol. 221, 195– 203. 10.1002/jcp.21845 19507189 PMC2805018 · DOI
  73. Paul J. Strickland S. Melchor J. P. (2007). Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer’s disease. J. Exp. Med. 204, 1999– 2008. 10.1084/jem.20070304 17664291 PMC2118680 · DOI · Paper page
  74. Qian Z. Gilbert M. E. Colicos M. A. Kandel E. R. Kuhl D. (1993). Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 361, 453– 457. 10.1038/361453a0 8429885 · DOI
  75. Rubel C. Fernández G. C. Dran G. Bompadre M. B. Isturiz M. A. Palermo M. S. (2001). Fibrinogen promotes neutrophil activation and delays apoptosis. J. Immunol. 166, 2002– 2010. 10.4049/jimmunol.166.3.2002 11160249 · DOI
  76. Ryu J. K. Davalos D. Akassoglou K. (2009). Fibrinogen signal transduction in the nervous system. J. Thromb. Haemost. 7(Suppl. 1), 151– 154. 10.1111/j.1538-7836.2009.03438.x 19630789 PMC2888044 · DOI
  77. Ryu J. K. McLarnon J. G. (2009). A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain. J. Cell. Mol. Med. 13, 2911– 2925. 10.1111/j.1582-4934.2008.00434.x 18657226 PMC4498946 · DOI · Paper page
  78. Sappino A. P. Madani R. Huarte J. Belin D. Kiss J. Z. Wohlwend A.. (1993). Extracellular proteolysis in the adult murine brain. J. Clin. Invest. 92, 679– 685. 10.1172/jci116637 8349806 PMC294901 · DOI
  79. Schachtrup C. Lu P. Jones L. L. Lee J. K. Lu J. Sachs B. D.. (2007). Fibrinogen inhibits neurite outgrowth via beta3 integrin-mediated phosphorylation of the EGF receptor. Proc. Natl. Acad. Sci. U S A 104, 11814– 11819. 10.1073/pnas.0704045104 17606926 PMC1913857 · DOI · Paper page
  80. Schachtrup C. Ryu J. K. Helmrick M. J. Vagena E. Galanakis D. K. Degen J. L.. (2010). Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage. J. Neurosci. 30, 5843– 5854. 10.1523/JNEUROSCI.0137-10.2010 20427645 PMC2871011 · DOI
  81. Shlosberg D. Benifla M. Kaufer D. Friedman A. (2010). Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat. Rev. Neurol. 6, 393– 403. 10.1038/nrneurol.2010.74 20551947 PMC3625732 · DOI · Paper page
  82. Siconolfi L. B. Seeds N. W. (2001). Mice lacking tPA, uPA, or plasminogen genes showed delayed functional recovery after sciatic nerve crush. J. Neurosci. 21, 4348– 4355. 11404420 PMC6762762
  83. Skogen W. F. Senior R. M. Griffin G. L. Wilner G. D. (1988). Fibrinogen-derived peptide B beta 1–42 is a multidomained neutrophil chemoattractant. Blood 71, 1475– 1479. 3359049
  84. Skrzypiec A. E. Maiya R. Chen Z. Pawlak R. Strickland S. (2009). Plasmin-mediated degradation of laminin gamma-1 is critical for ethanol-induced neurodegeneration. Biol. Psychiatry 66, 785– 794. 10.1016/j.biopsych.2009.05.021 19577227 PMC2757483 · DOI
  85. Smiley S. T. King J. A. Hancock W. W. (2001). Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J. Immunol. 167, 2887– 2894. 10.4049/jimmunol.167.5.2887 11509636 · DOI
  86. Sokrab T. E. Kalimo H. Johansson B. B. (1990). Parenchymal changes related to plasma protein extravasation in experimental seizures. Epilepsia 31, 1– 8. 10.1111/j.1528-1157.1990.tb05352.x 2303007 · DOI
  87. Stamatovic S. M. Keep R. F. Andjelkovic A. V. (2008). Brain endothelial cell-cell junctions: how to “open” the blood brain barrier. Curr. Neuropharmacol. 6, 179– 192. 10.2174/157015908785777210 19506719 PMC2687937 · DOI
  88. Su E. J. Fredriksson L. Geyer M. Folestad E. Cale J. Andrae J.. (2008). Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat. Med. 14, 731– 737. 10.1038/nm1787 18568034 PMC2811427 · DOI
  89. Syrovets T. Simmet T. (2004). Novel aspects and new roles for the serine protease plasmin. Cell. Mol. Life Sci. 61, 873– 885. 10.1007/s00018-003-3348-5 15095009 PMC11138900 · DOI
  90. Takada Y. Ono Y. Saegusa J. Mitsiades C. Mitsiades N. Tsai J.. (2010). A T cell-binding fragment of fibrinogen can prevent autoimmunity. J. Autoimmun. 34, 453– 459. 10.1016/j.jaut.2009.11.017 20036106 PMC2860040 · DOI
  91. Tanno H. Nockels R. P. Pitts L. H. Noble L. J. (1992). Breakdown of the blood-brain barrier after fluid percussive brain injury in the rat. Part 1: distribution and time course of protein extravasation. J. Neurotrauma 9, 21– 32. 10.1089/neu.1992.9.21 1619673 · DOI
  92. Tsirka S. E. Gualandris A. Amaral D. G. Strickland S. (1995). Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 377, 340– 344. 10.1038/377340a0 7566088 · DOI
  93. Tucsek Z. Toth P. Sosnowska D. Gautam T. Mitschelen M. Koller A.. (2014). Obesity in aging exacerbates blood-brain barrier disruption, neuroinflammation and oxidative stress in the mouse hippocampus: effects on expression of genes involved in beta-amyloid generation and Alzheimer’s disease. J. Gerontol. A Biol. Sci. Med. Sci. 69, 1212– 1226. 10.1093/gerona/glt177 24269929 PMC4172034 · DOI
  94. Tyagi N. Roberts A. M. Dean W. L. Tyagi S. C. Lominadze D. (2008). Fibrinogen induces endothelial cell permeability. Mol. Cell. Biochem. 307, 13– 22. 10.1007/s11010-007-9579-2 17849175 PMC2811266 · DOI
  95. van Oijen M. Witteman J. C. Hofman A. Koudstaal P. J. Breteler M. M. (2005). Fibrinogen is associated with an increased risk of alzheimer disease and vascular dementia. Stroke 36, 2637– 2641. 10.1161/01.str.0000189721.31432.26 16269641 · DOI · Paper page
  96. Verbout N. G. Yu X. Healy L. D. Phillips K. G. Tucker E. I. Gruber A.. (2015). Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis. Metab. Brain Dis. 30, 57– 65. 10.1007/s11011-014-9558-8 24810631 PMC4225189 · DOI
  97. Viggars A. P. Wharton S. B. Simpson J. E. Matthews F. E. Brayne C. Savva G. M.. (2011). Alterations in the blood brain barrier in ageing cerebral cortex in relationship to alzheimer-type pathology: a study in the MRC-CFAS population neuropathology cohort. Neurosci. Lett. 505, 25– 30. 10.1016/j.neulet.2011.09.049 21970975 · DOI
  98. Vivien D. Gauberti M. Montagne A. Defer G. Touzé E. (2011). Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J. Cereb. Blood Flow Metab. 31, 2119– 2134. 10.1038/jcbfm.2011.127 21878948 PMC3210341 · DOI
  99. Wagner O. F. de Vries C. Hohmann C. Veerman H. Pannekoek H. (1989). Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. J. Clin. Invest. 84, 647– 655. 10.1172/jci114211 2503541 PMC548928 · DOI
  100. Wang X. Lee S. R. Arai K. Tsuji K. Rebeck G. W. Lo E. H. (2003). Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat. Med. 9, 1313– 1317. 10.1038/nm926 12960961 · DOI
  101. Xu G. Zhang H. Zhang S. Fan X. Liu X. (2008). Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. Int. J. Clin. Pract. 62, 1070– 1075. 10.1111/j.1742-1241.2007.01268.x 17916180 · DOI · Paper page
  102. Yang Y. Tian S. J. Wu L. Huang D. H. Wu W. P. (2011). Fibrinogen depleting agent batroxobin has a beneficial effect on experimental autoimmune encephalomyelitis. Cell. Mol. Neurobiol. 31, 437– 448. 10.1007/s10571-010-9637-2 21165693 PMC11498529 · DOI
  103. Yepes M. Sandkvist M. Moore E. G. Bugge T. H. Strickland D. K. Lawrence D. A. (2003). Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J. Clin. Invest. 112, 1533– 1540. 10.1172/jci19212 14617754 PMC259131 · DOI
  104. Zamolodchikov D. Chen Z. L. Conti B. A. Renné T. Strickland S. (2015). Activation of the factor XII-driven contact system in Alzheimer’s disease patient and mouse model plasma. Proc. Natl. Acad. Sci. U S A 112, 4068– 4073. 10.1073/pnas.1423764112 25775543 PMC4386355 · DOI
  105. Zamolodchikov D. Strickland S. (2012). Abeta delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin. Blood 119, 3342– 3351. 10.1182/blood-2011-11-389668 22238323 PMC3321860 · DOI

Cited by

Sorted by citations

Authors
Bardehle, S., Rafalski, V. A., & Akassoglou, K.
Affiliations
University of California, San Francisco (US)
Corresponding author
Akassoglou, Katerina
ORCID
Akassoglou, Katerina
Venue
Frontiers in Cellular Neuroscience
Publisher
Frontiers Media SA
Published
2015-09-16
Volume
9
Pages
354-354
ISSN
1662-5102 (ISSN-L)
DOI
10.3389/fncel.2015.00354
PMC
PMC4584986
OpenAlex
W1942180589
Cited by
76
References
5
Citations by year
2026: 4 · 2025: 6 · 2024: 6 · 2023: 6 · 2022: 5 · 2021: 9 · 2020: 5 · 2019: 4 · 2018: 11 · 2017: 13 · 2016: 7
FWCI
1.83
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Cellular Neuroscience (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute of Neurological Disorders and Stroke (NS052189, NS082976, NS51470)
  • National Multiple Sclerosis Society (RG 4985A3)
  • American Heart Association
  • Deutsche Forschungsgemeinschaft
  • Conrad N. Hilton Foundation
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Blood properties and coagulation
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords
neurovascular unit, coagulation, fibrinolysis, plasminogen activation, plasmin system, fibrin, neuroinflammation, immune cell trafficking, blood-brain barrier, multiple sclerosis, Alzheimer's disease, stroke, biomarkers, therapeutic target, neurodegeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review